Charkiewicz AE, Garley M, Ratajczak-Wrona W, Jabłońska E, Miltyk W, Motyka J, Omeljaniuk WJ. The diagnostic potential of novel biomarkers of hypertension in men.
Arch Med Sci 2022;
18:1666-1671. [PMID:
36457990 PMCID:
PMC9710276 DOI:
10.5114/aoms/153500]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 09/04/2022] [Indexed: 11/09/2022] Open
Abstract
INTRODUCTION
The present study aimed to evaluate the diagnostic usefulness of selected novel parameters as biomarkers of hypertension: miR-145-5p, miR-1-3p, miR-423-5p, PCSK9, MyBPC3, NOX1, and CYBb, and NCF2, DNase 1, anti-MPO and anti-PR3 antibodies.
METHODS
We present the data of men with normal blood pressure, diagnosed hypertension, confirmed hypertension, and hypertension and coexisting coronary artery disease.
RESULTS
Elevated levels of miR-145-5p, miR-1-3p, and miR-423-5p and high levels of PCSK9, MyBPC3, and DNase 1 were observed in all groups of hypertensive men. We showed decreased levels of NOX1 and CYBb, and an elevated level of NCF2.
CONCLUSIONS
PCSK9 shows the greatest potential as an early biomarker of screening-detected hypertension.
Collapse